Scolr Pharma adds Nuprin to portfolio
BOTHELL, Wash. Scolr Pharma earlier this year acquired the rights to the Nuprin brand name from Advanced Healthcare Distributors, an affiliate company of CVS Caremark, in a deal worth $180,000.
“Our acquisition of this globally recognized name will provide us with additional opportunities for ibuprofen-based products,” stated Stephen Turner, Scolr Pharma president and CEO. “We expect that the acquisition will allow us to generate potential near-term sales of immediate release 200 mg ibuprofen tablets, in addition to providing us with enhanced options on our extended release ibuprofen program.”
Proantinox may reduce UTI incidence in women, study suggests
EDISON, N.J. A recent study being published in the journal Urology found that Proantinox, a proprietary cranberry-based blend found in DSE Healthcare Solutions’ Cystex liquid cranberry complex with Proantinox, is safe and effective in significantly reducing the incidence of urinary tract infections in women at risk for recurring infections.
The study, conducted by Aaron Katz, professor of clinical urology at Columbia University college of physicians and surgeons, also found that those women who took the recommended doses of the formula significantly improved quality of life as measured by the American Urological Association Symptom Index.
“The objectives of this study initially were to determine the safety, tolerability and maximum dose necessary of the proprietary Proantinox formula, but the secondary finding of efficacy was so significant, we felt it was worth noting,” stated Katz. “Normally you would expect at least 32% to 36% of the participants, based on history, to have at least one more infection or UTI symptoms during the study period, but we found only 9% of the sample had this occur.”
The study looked at 28 women, ages 18 to 75 years, who had experienced at least two or more urinary tract infections in the past six months. In addition to the tolerability and efficacy findings, questionnaires were also completed at baseline, week four and week 12 to measure overall health and quality of life based on the AUA Symptom Index.
Perrigo gains OTC rights for generic Allegra products
ALLEGAN, Mich. Perrigo on Tuesday announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of fexofenadine HCl 180 mg and 60 mg tabs, plus fexofenadine HCl 60 mg and pseudoephedrine 120 mg tabs, the generic versions of Sanofi-Aventis’ Allegra and Allegra D-12 products, respectively.
Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of symptoms associated with seasonal allergies. Sanofi-Aventis has applied to the Food and Drug Administration for the Rx-to-OTC switch of these drugs, even going so far as to acquire OTC supplier Chattem as an in-house distribution arm for the allergy medicine.
It is assumed Allegra will be approved for its switch OTC, especially as an FDA advisory committee in 2001 recommended Allegra be eligible for switch.
Prior to generic competition entering the fexofenadine Rx market in 2005, Allegra 180 mg and 60 mg had combined annual sales of approximately $1.5 billion, and in 2009, Allegra D-12 had annual sales of $600 million according to data provided by Wolters-Kluwer.